Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

The narrative shifted in March 2024, when the US Food and Drug Administration (FDA) approved resmetirom (Madrigal Pharmaceuticals’ Rezdiffra), the first-ever medication green-lit for MASH.

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

The US regulator has cleared Madrigal’s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non-alcoholic steatohepatitis (NASH) – who have moderate to ...